Valneva

VALN

Market cap $851M

NEW YORK , Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext.

NEW YORK , Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK , Oct. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Saint-Herblain (France), October 6, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has entered into a debt facility for up to $500 million in non-dilutive financing with funds managed by Pharmakon Advisors, LP. An initial tranche of $215 million will be used to repay in full the Company's existing debt facility with Deerfield Management Company and OrbiMed, inclusive of associated fees and expenses. The remaining up to $285 million may be drawn in the future for potential business development subject to mutual agreement between the parties. The Agreement was executed today and the initial tranche is expected to be funded in the coming weeks.

NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Saint-Herblain (France), September 30, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive antibody persistence data four years after vaccination with a single dose of its chikungunya vaccine IXCHIQ®. The results are in line with Valneva's expectations for this vaccine, confirming a strong and long-lasting antibody persistence across all age groups investigated. The four-year persistence data are in line with previous persistence data1 , 2 , 3, further highlighting a key advantage of the vaccine.

NEW YORK , Sept. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN).

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Valneva SE (“Valneva” or the “Company”) (NASDAQ: VALN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN).

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Valneva (VALN) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Valneva and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.